<DOC>
	<DOCNO>NCT00001074</DOCNO>
	<brief_summary>To determine safety tolerability hydroxyurea two dos alone combination didanosine ( ddI ) . To compare short term antiviral effect ddI monotherapy versus hydroxyurea plus ddI , measure plasma RNA level 8 week therapy . [ AS PER AMENDMENT 10/1/97 : Accrual arm involve hydroxyurea alone close . ] Current antiviral therapy HIV-1 limit choice , lack sustain clinical benefit drug . The mechanisms account lack prolonged inhibition viral replication agent fully understood . The activity RT inhibitor might potentiate inhibit host cellular enzyme essential efficient HIV reverse transcription . Based information , comparison antiviral effect ddI monotherapy hydroxyurea plus ddI , cellular enzyme ribonucleotide reductase potential target , do .</brief_summary>
	<brief_title>The Safety Effectiveness Hydroxyurea ddI Used Individually Together HIV-Infected Patients</brief_title>
	<detailed_description>Current antiviral therapy HIV-1 limit choice , lack sustain clinical benefit drug . The mechanisms account lack prolonged inhibition viral replication agent fully understood . The activity RT inhibitor might potentiate inhibit host cellular enzyme essential efficient HIV reverse transcription . Based information , comparison antiviral effect ddI monotherapy hydroxyurea plus ddI , cellular enzyme ribonucleotide reductase potential target , do . This 24-week study , two 12-week treatment period . Patients randomize one five treatment arm base upon patient 's history antiretroviral therapy ( naive vs. experience ) . The five treatment arm : 1. ddI plus hydroxyurea placebo . 2. hydroxyurea ( low dose ) plus ddI placebo 4 week ; hydroxyurea ( high dose ) plus ddI . 3. hydroxyurea ( high dose ) plus ddI placebo 4 week ; hydroxyurea ( high dose ) plus ddI . 4. hydroxyurea ( low dose ) plus ddI . 5. hydroxyurea ( high dose ) plus ddI . After completion week 12 , patient combination therapy remain current therapy patient ddI plus placebo hydroxyurea replace placebo 1 2 assign dos ( 1:1 randomization ) . AS PER AMENDMENT 5/5/97 : If 24-week treatment period , patient RNA level less equal 5,000 copies/ml less 20,000 copies/ml great 1 log10 decline baseline , option continue therapy open-label ddI plus hydroxyurea additional 24 week . AS PER AMENDMENT 10/1/97 : Accrual arm involve hydroxyurea alone close . Patients randomize one three treatment arm , follow : 1. hydroxyurea placebo plus ddI . 2. hydroxyurea ( low dose ) plus ddI . 3. hydroxyurea ( high dose ) plus ddI .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : AS PER AMENDMENT 5/5/97 : PCP prophylaxis trimethoprim/sulfamethoxazole Dapsone . Patients must : HIV1 infection . AS PER AMENDMENT 5/5/97 : CD4 count 200 700 cells/mm3 within 60 day prior study entry . AS PER AMENDMENT 10/1/97 : HIV RNA plasma level &lt; 20,000 copies/ml within 60 day enrollment ( obtain laboratory certify perform Roche Monitor assay ) . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : CMV , MAC , toxoplasmosis , disseminate fungal infection require acute chronic therapy . Significant medical illness determine investigator . Active diagnosis malignancy , include visceral Kaposi 's sarcoma extensive cutaneous Kaposi 's sarcoma systemic chemotherapy anticipate within next 24 week . Current Grade 2 great peripheral neuropathy . Concurrent Medication : Excluded : Acute chronic therapy CMV , MAC , toxoplasmosis , disseminate fungal infection . AS PER AMENDMENT 5/5/97 : All antiretroviral medication provide study . Systemic chemotherapy active malignancy , include systemic treatment KS . Agents myelosuppressive potential , include tegretol , carboplatin , carmustine , cyclophosphamide fluorouracil . Granulocyte colony stimulate factor ( GCSF ) except hydroxyurea match placebo hold . Drugs associate peripheral neuropathy , include : hydralazine , disulfiram , nitrofurantoin , cisplatinum , diethyldithiocarbamate , gold , rifampin , chloramphenicol , clioquinol , ethambutol , ethionamide , glutethimide , sodium cyanate , thalidomide . Patients prior condition exclude : History transfusion dependent anemia , define history repeat transfusion two unit red blood cell . At discretion investigator , history pancreatitis . Prior Medication : Excluded : More 2 week prior treatment ddI . AS PER AMENDMENT 5/5/97 : Other antiretrovirals must discontinue least 14 day prior randomization . Prior hydroxyurea . Any candidate HIV vaccine agent potential immune modulate effect within past 30 day . Any colony stimulate factor erythropoietin within past 60 day . Prior Treatment : Excluded : Transfusion red blood cell within past 60 day . Risk Behavior : Excluded : At investigator 's discretion , active substance abuse , include alcohol abuse interfere compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Hydroxyurea</keyword>
</DOC>